A personalised vaccine cut melanoma's return by 42 percent in a 1,137-patient trial

For people whose melanoma has been removed but who face a high risk of it returning, a vaccine made from their own tumour's genetic fingerprint may help keep the cancer away. In a phase 3 trial of 1,137 patients presented at the European Society for Medical Oncology congress in Madrid, adding the personalised mRNA vaccine intismeran to standard immunotherapy reduced the risk of recurrence or death by 42 percent compared with immunotherapy alone. Professor Georgina Long of Melanoma Institute Australia presented the results, which will be published in the New England Journal of Medicine.

SDG 3 · Good health and well-being — Mechanism: tech innovation